Vascular endothelial growth factor (VEGF), prostaglandin E2 (PGE2) and active renin in hypertension of adrenal origin

Journal of Endocrinological Investigation

Volumn 27, Issue 8, 2004, Pages 742-746

  Zacharieva, S ^a   Atanassova, I ^a   Orbetzova, M ^a   Kirilov, G ^a   Nachev, E ^a   Kalinov, K ^a   Shigarminova, R ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Active renin; Adrenal hypertension; Angiogenesis; PGE2; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; CATECHOLAMINE; GLUCOCORTICOID; MINERALOCORTICOID; PROSTAGLANDIN E2; RENIN; VASCULOTROPIN;

ADRENAL GLAND; ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CARDIOVASCULAR RISK; CONTROLLED STUDY; CUSHING DISEASE; CUSHING SYNDROME; DIAGNOSTIC PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; PROTEIN FUNCTION;

EID: 10244235365     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347516     Document Type: Article

References (36)

1. Katoh R. Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor. Microsc Res Tech 2003, 60: 181-5.
2. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18: 4-25.
3. Ku DD, Zaleski JK, Liu SY, Brock TA. Vascular endothelial growth factor induced EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993, 256: H586-92.
4. Van der Zee R, Murohara T, Luo Z, et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997, 95: 1030-7.
5. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996, 63: 77-82.
6. Horowitz J, Hariawala M, Sheriff DD, Keyt B, Symes JF. In vivo administration of vascular endothelial growth factor is associated with EDRF-dependent decrease in systemic hypotension in porcine and rabbit. Circulation 1995, 92:1-630 (abstract).
7. Yang R, Thomas G, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamic and cardiac performance. J Cardiovasc Pharmacol 1996, 27: 838-44.
8. Eppler SM, McCluskey ER, Henry TD, Simons M, Giordano FJ, Zioncheck TF. Unique kinetics and hemodynamics of vascular endothelial growth factor (rhVEGF) following intracoronary and intravenous infusion in humans. J Am Coll Cardiol 2000, 35 (Suppl A): 37A (abstract).
9. Liu M-H, Jin H, Floten S, et al. Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats. J Pharmacol Exp Ther 2001, 296: 473-7.
10. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFIt-1) in essential hypertension. Am J Cardiol 2001, 87: 805-7.
11. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001, 286: 923-8.
12. Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001, 31: 325-48.
13. Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 2001, 280: H885-91.
14. Pupilli C, Lasagni L, Romagnani P, et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999, 10: 245-55.
15. Saijonmaa O, Nyma T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 2001, 280: H885-91.
16. Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995, 18: 495-511.
17. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Des 2003, 9: 1733-44.
18. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001, 104: 735-40.
19. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003, 16: 11-20.
20. Felmeden DC, Spencer CG, Blann AD, Beevers DG, Lip GY. Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Intern Med 2003, 253: 81-91.
21. Cucina A, Borrelli V, Randone B, Coluccia P, Sapienza P, Cavallaro A. Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells. J Surg Res 2003, 109: 16-23.
22. Katoh R. Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor. Microsc Res Tech 2003, 60: 181-5.
23. Bernini GP, Moretti A, Bonadio AG, et al. Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab 2002, 87: 4961-5.
24. Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 2002, 161: 1235-46.
25. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 2003, 111: 458-64.
26. Thomas M, Keramidas M, Monchaux E, Feige JJ. Role of adrenocorticotropic hormone in the development and maintenance of the adrenal cortical vasculature. Microsc Res Tech 2003, 61: 247-51
27. Heikkila P, Arola J, Voutilainen R, Salmenkivi K, Kahri AL, Liu J. Expression of vascular endothelial growth factor in human adrenals. Endocr Res 2000, 26: 867-71.
28. Gaillard I, Keramidas M, Liakos P, Vilgrain I, Feige JJ, Vittet D. ACTH-regulated expression of vascular endothelial growth factor in the adult bovine adrenal cortex: a possible role in the maintenance of the microvasculature. J Cell Physiol 2000, 185: 226-34.
29. Yamada S, Takada K. Angiogenesis in pituitary adenomas. Microsc Res Tech 2003, 60: 236-43.
30. Hunter JA, Skelly RH, Aylwin SJ, et al. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 2003, 148: 203-11.
31. 2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 2003, 102: 1966-77.
32. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003, 112: 67-75.
33. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996, 98: 671-79.
34. Takeshita S, Tomiyama H, Yokoyama N, et al. Angiotensin converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res 2001, 52: 314-20.
35. Tenschert W, Baumgart P, Greminger P, Vetter W, Vetter H. Pathogenetic aspects of hypertension in Cushing's syndrome. Cardiology 1985, 72 (Suppl 1): 84-90.
36. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986, 62: 275-9.